Intraperitoneal Radioimmunotherapy with Human Monoclonal IGM in Nude Mice with Peritoneal Carcinomatosis-Reference-Cited by-同舟云学术

Intraperitoneal Radioimmunotherapy with Human Monoclonal IGM in Nude Mice with Peritoneal Carcinomatosis

Published:2000-02 Issue:1 Volume:15 Page:53-64
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Borchardt Paul E.,Quadri Syed M.,Freedman Ralph S.,Vriesendorp Huibert M.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.2000.15.53

Reference17 articles.

1. Early detection of ovarian cancer

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer;Journal of Nuclear Medicine;2018-04-19

2. Radioimmunotherapy for peritoneal cancers;Immunotherapy;2013-04

3. Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest;European Journal of Nuclear Medicine and Molecular Imaging;2012-08-08

4. High molecular mass radioimmunoconjugates are promising for intraperitoneal α-emitter immunotherapy due to prolonged retention in the peritoneum;Nuclear Medicine and Biology;2012-07

5. Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model;Nuclear Medicine and Biology;2012-01